Additional file 7: of Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors Kohei Shitara Taroh Satoh Satoru Iwasa Kensei Yamaguchi Kei Muro Yoshito Komatsu Tomohiro Nishina Taito Esaki Jun Hasegawa Yasuyuki Kakurai Emi Kamiyama Tomoko Nakata Kota Nakamura Hayato Sakaki Ichinosuke Hyodo 10.6084/m9.figshare.9631238.v1 https://springernature.figshare.com/articles/figure/Additional_file_7_of_Safety_tolerability_pharmacokinetics_and_pharmacodynamics_of_the_afucosylated_humanized_anti-EPHA2_antibody_DS-8895a_a_first-in-human_phase_I_dose_escalation_and_dose_expansion_study_in_patients_with_advanced_solid_tumo/9631238 Disposition of patients. †One patient was excluded from the efficacy analysis set because no efficacy data were available. ‡One patient was excluded from the PK analysis set because no PK data were available. Abbreviation: PK, pharmacokinetics. (TIF 224 kb) 2019-08-15 05:01:24 Erythropoietin-producing hepatocellular receptor A2 Gastric cancer Esophageal cancer Advanced solid tumors DS-8895a Antibody-dependent cellular cytotoxicity Phase I study